Effects of Th22 cells and IL-22 in tumors

Abstract

Liu Guofang, Xiang Xiaoxing. Effects of Th22 cells and IL-22 in tumors[J]. Journal of International Oncology, 2014, 41(2): 93-96.

［1］ Wolk K, Witte E, Witte K, et al. Biology of interleukin22［J］. Semin Immunopathol, 2010, 32(1): 17-31. ［2］ Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17cellmediated autoimmunity to environmental toxins［J］. Nature, 2008, 453(7191): 106-109. ［3］ Dardalhon V, Awasthi A, Kwon H, et al. IL4 inhibits TGFbetainduced Foxp3+ T cells and, together with TGFbeta, generates IL9+ IL10+ Foxp3() effector T cells［J］. Nat Immunol, 2008, 9(12):1347-1355. ［4］ Fujita H, Nograles KE, Kikuchi T, et al. Human Langerhans cells induce distinct IL22producing CD4+ T cells lacking IL17 production［J］. Proc Natl Acad Sci USA, 2009, 106(51):21795-21800. ［5］ Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function［J］. Cell, 2001, 104(1):9-19. ［6］ Leipe J, Schramm MA, Grunke M, et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis［J］. Ann Rheum Dis, 2011, 70(8):1453-1457. ［7］ Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL22 signaling in intestinal epithelial cells to mucosal wound healing［J］. J Exp Med, 2009, 206(7):1465-1472. ［8］ Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)17, T(H)1 and T(H)2 cells［J］. Nat Immunol, 2009, 10(8):864-871. ［9］ Xie MH, Aggarwal S, Ho WH, et al. Interleukin (IL)22, a novel human cytokine that signals through the interferon receptorrelated proteins CRF24 and IL22R［J］. J Biol Chem, 2000, 275(40):31335-31339. ［10］ Jones BC, Logsdon NJ, Walter MR. Structure of IL22 bound to its highaffinity IL22R1 chain［J］. Structure, 2008, 16(9):1333-1344. ［11］ Eyerich S, Wagener J, Wenzel V, et al. IL22 and TNFα represent a key cytokine combination for epidermal integrity during infection with Candida albicans［J］. Eur J Immunol, 2011, 41(7):1894-1901. ［12］ Wolk K, Kunz S, Witte E, et al. IL22 increases the innate immunity of tissues［J］. Immunity, 2004, 21(2):241-254. ［13］ Tian T, Yu S, Ma D. Th22 and related cytokines in inflammatory and autoimmune diseases［J］. Expert Opin Ther Targets, 2013, 17(2):113125. ［14］ Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression［J］. Semin Cancer Biol, 2008, 18(5):330-337. ［15］ Jiang R, Tan Z, Deng L, Chen Y, et al. Interleukin22 promotes human hepatocellular carcinoma by activation of STAT3［J］. Hepatology, 2011, 54(3):900-909. ［16］ Park O, Wang H, Weng H, et al. In vivo consequences of liverspecific interleukin22 expression in mice: implications for human liver disease progression［J］. Hepatology, 2011, 54(1):252-261. ［17］ Liu T, Peng L, Yu P, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer［J］. J Clin Immunol, 2012, 32(6):1332-1339. ［18］ Zhuang Y, Peng LS, Zhao YL, et al. Increased intratumoral IL22producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival［J］. Cancer Immunol Immunother, 2012, 61(11):1965-1975. ［19］ Zhang W, Chen Y, Wei H, et al. Antiapoptotic activity of autocrine interleukin22 and therapeutic effects of interleukin22small interfering RNA on human lung cancer xenografts［J］. Clin Cancer Res, 2008, 14(20):6432-6439. ［20］ Ye ZJ, Zhou Q, Yin W, et al. Interleukin 22producing CD4+ T cells in malignant pleural effusion［J］. Cancer Lett, 2012, 326(1):23-32. ［21］ Liu LM, Zhang XX, Zhang YM. The change of peripheral blood Th22 cells in patients with acute myeloid leukemia［J］. Zhonghua Xue Ye Xue Za Zhi, 2012, 33(2):133-135. ［22］ Weber GF, Gaertner FC, Erl W, et al. IL22mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2M phase［J］. J Immunol, 2006, 177(11):8266-8272.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Effects of Th22 cells and IL-22 in tumors

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments